title: Innovative agents in multiple myeloma.
abstract: Multiple myeloma (MM) remains an incurable cancer of the bone marrow plasma cells. However, the overall survival of patients with MM has increased dramatically within the past decade. This is due, in part, to newer agents such as immunomodulatory drugs (lenalidomide, thalidomide, and pomalidomide) and proteasome inhibitors (bortezomib, carfilzomib, MLN9708). These and several other new classes of drugs have arisen from an improved understanding of the complex environment in which genetic changes occur. Improved understanding of genetic events will enable clinicians to better stratify risk before and during therapy, tailor treatment, and test the value of personalized interventions. The ultimate goal in this incurable disease setting is to reduce the impact of cancer- or chemotherapy-related side effects. Nurses and advanced practitioners are integral to the treatment team. Thus, each should be aware of changes to the current drug landscape. Targeted drugs with sophisticated mechanisms of action are currently under investigation. Patients gain access to newer drugs within the context of clinical trials. Awareness of such trials will help accrual and determine if therapeutic benefit exists. In this article, we will describe new agents with unique and targeted mechanisms of action that have activity in patients with relapsed and/or refractory multiple myeloma.
authors.affiliation: Cleveland Clinic Foundation, Cleveland, Ohio, and University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Beth
authors.initials: B
authors.lastname: Faiman
authors.affiliation: Cleveland Clinic Foundation, Cleveland, Ohio, and University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Tiffany
authors.initials: T
authors.lastname: Richards
references.citation: Bone Marrow Res. 2011;2011:924058
references.pmid: 22046572
references.citation: J Clin Oncol. 2011 Nov 10;29(32):4243-9
references.pmid: 21990396
references.citation: Br J Haematol. 2012 Aug;158(4):472-80
references.pmid: 22640031
references.citation: Blood. 2010 Aug 5;116(5):679-86
references.pmid: 20385792
references.citation: J Clin Oncol. 2011 Sep 1;29(25):3427-34
references.pmid: 21825263
references.citation: Clin Cancer Res. 2008 May 1;14(9):2775-84
references.pmid: 18451245
references.citation: J Clin Oncol. 2011 Mar 20;29(9):1125-32
references.pmid: 21343556
references.citation: Ann Hematol. 2014 Jan;93(1):89-98
references.pmid: 24135804
references.citation: J Clin Oncol. 2010 Feb 20;28(6):1031-7
references.pmid: 20085941
references.citation: Blood. 2009 Aug 20;114(8):1489-97
references.pmid: 19498019
references.citation: Semin Oncol. 2013 Oct;40(5):554-66
references.pmid: 24135400
references.citation: Cancer Res. 2005 Dec 15;65(24):11712-20
references.pmid: 16357183
references.citation: Blood Cancer J. 2014 Feb 21;4:e182
references.pmid: 24562384
references.citation: J Immunol. 2011 Feb 1;186(3):1840-8
references.pmid: 21187443
references.citation: Blood. 2013 Oct 3;122(14):2331-7
references.pmid: 23950178
references.citation: J Biol Chem. 2012 Jun 22;287(26):21796-805
references.pmid: 22556409
references.citation: Blood. 2008 Mar 1;111(5):2516-20
references.pmid: 17975015
references.citation: Clin Cancer Res. 2008 Feb 1;14(3):865-74
references.pmid: 18245550
references.citation: Blood. 2010 Nov 25;116(22):4560-8
references.pmid: 20686120
references.citation: J Natl Compr Canc Netw. 2009 Oct;7(9):908-42
references.pmid: 19878637
references.citation: Blood. 2004 Dec 15;104(13):4188-93
references.pmid: 15319277
references.citation: J Immunol. 2010 Jul 1;185(1):220-30
references.pmid: 20505142
references.citation: Br J Haematol. 2012 Oct;159(1):58-66
references.pmid: 22861192
references.citation: Lancet Oncol. 2011 Mar;12(3):263-72
references.pmid: 21345726
references.citation: Cancer. 2013 Jan 15;119(2):339-47
references.pmid: 22811009
references.citation: Blood Cancer J. 2011 Oct;1(10):e41
references.pmid: 22829073
references.citation: Br J Haematol. 2013 May;161(3):357-66
references.pmid: 23432640
references.citation: Br J Haematol. 2011 Aug;154(4):533-5
references.pmid: 21517811
references.citation: Blood. 2009 Apr 30;113(18):4309-18
references.pmid: 19196658